Myriad Genetics Inc
MYGNMyriad Genetics Inc is a biotechnology company specializing in molecular diagnostics and genetic testing. It develops and commercializes tests that assess risk for various diseases, including cancer, women's health conditions, and other hereditary disorders. The company focuses on personalized medicine solutions to help guide clinical decision-making and improve patient outcomes.
Company News
The pan-genomic and multi-gene panel testing market is projected to grow from US$ 8.9 billion in 2024 to US$ 25.9 billion by 2032, driven by a 12.04% CAGR. Growth is fueled by rising clinical adoption of genomics-driven diagnostics, FDA approvals of comprehensive genomic profiling tests, advances in NGS technology and bioinformatics, and expandin...
The global reproductive genetics market is projected to grow from USD 7.31 billion in 2025 to USD 16.67 billion by 2032, with a CAGR of 12.5%. Growth is driven by rising demand for genetic testing, preimplantation genetic testing (PGT), and non-invasive prenatal testing (NIPT), though ethical and legal challenges continue to limit expansion. Nort...
4D Path developed a computational platform that can predict chemotherapy response in early-stage triple-negative breast cancer using routine biopsy images, demonstrating potential for personalized cancer treatment prediction.
Myriad Genetics added F8 and FXN genes to its Foresight® Carrier Screen Universal Plus Panel, enhancing genetic screening capabilities for hemophilia A and Friedreich's ataxia, while maintaining compliance with ACMG recommendations.
Myriad Genetics published a study in The Lancet Oncology demonstrating the effectiveness of their Precise® MRD test in detecting circulating tumor DNA levels in patients with oligometastatic clear-cell renal cell carcinoma, potentially enabling treatment de-escalation.
